Mon. 8 Apr 2024, 7:10am ET
Benzinga
Biotech, News, Health Care, General
- Consistent safety and efficacy profiles across adult and pediatric populations –
- Majority of pediatric patients who achieved an overall response proceeded to transplant; patients receiving post-transplant revumenib maintenance remained in remission as of data cutoff date –
- No treatment-related discontinuations or dose reductions